PHARMACOKINETICS OF BRIVARACETAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT

被引：0
|
作者：
Stockis, A. [1 ]
Jacobs, T. [1 ]
Leonard, M. [1 ]
Sargentini-Maier, M. L. [1 ]
机构：
[1] UCB Pharma SA, Braine Lalleud, Belgium
来源：
EPILEPSIA | 2010年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：122 / 123
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
    Luzelena Caro
    Larissa Wenning
    Hwa-Ping Feng
    Zifang Guo
    Lihong Du
    Pratik Bhagunde
    Christine Fandozzi
    Deborah Panebianco
    William L. Marshall
    Joan R. Butterton
    Marian Iwamoto
    Wendy W. Yeh
    European Journal of Clinical Pharmacology, 2019, 75 : 665 - 675
  • [22] Brivaracetam Disposition in Renal Impairment
    Sargentini-Maier, Maria Laura
    Sokalski, Antoni
    Boulanger, Pierre
    Jacobs, Tom
    Stockis, Armel
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (12): : 1927 - 1933
  • [23] Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
    Angelika Weil
    Paul Martin
    Robert Smith
    Stuart Oliver
    Peter Langmuir
    Jessica Read
    Karl-Heinz Molz
    Clinical Pharmacokinetics, 2010, 49 : 607 - 618
  • [24] Levetiracetam Pharmacokinetics in Japanese Subjects with Renal Impairment
    Junichi Yamamoto
    Nathalie Toublanc
    Yuji Kumagai
    Armel Stockis
    Clinical Drug Investigation, 2014, 34 : 819 - 828
  • [25] Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment
    Flanagan, S.
    Minassian, S. L.
    Morris, D.
    Ponnuraj, R.
    Marbury, T. C.
    Alcorn, H. W.
    Fang, E.
    Prokocimer, P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6471 - 6476
  • [26] Levetiracetam Pharmacokinetics in Japanese Subjects with Renal Impairment
    Yamamoto, Junichi
    Toublanc, Nathalie
    Kumagai, Yuji
    Stockis, Armel
    CLINICAL DRUG INVESTIGATION, 2014, 34 (11) : 819 - 828
  • [27] Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
    Weil, Angelika
    Martin, Paul
    Smith, Robert
    Oliver, Stuart
    Langmuir, Peter
    Read, Jessica
    Molz, Karl-Heinz
    CLINICAL PHARMACOKINETICS, 2010, 49 (09) : 607 - 618
  • [28] Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
    Custodio, Joseph M.
    Fordyce, Marshall
    Garner, William
    Vimal, Mona
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) : 5135 - 5140
  • [29] Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
    Ouwerkerk-Mahadevan S.
    Beumont-Mauviel M.
    Mortier S.
    Peeters M.
    Verloes R.
    Truyers C.
    Mannens G.
    Wynant I.
    Simion A.
    Drugs in R&D, 2015, 15 (3) : 261 - 270
  • [30] Effect of severe renal impairment on the pharmacokinetics of brigatinib
    Gupta, Neeraj
    Hanley, Michael J.
    Kerstein, David
    Tugnait, Meera
    Narasimhan, Narayana
    Marbury, Thomas C.
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1306 - 1314
12345